



March 13, 2023

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Representative
Director and President
(Securities code: 4891; Growth Market)
Inquiries: Go Ito, Director
(Telephone: +81-42-307-7480)

Notice regarding the development of TMS-007 (BIIB131)

TMS Co., Ltd. (the “Company”) hereby announces that Phase IIb clinical trial information for TMS-007(BIIB131) is registered and published on clinicaltrials.gov (<https://clinicaltrials.gov/>).

Phase:	Phase IIb
Sponsor:	Biogen
Estimated Enrollment:	760 participants
Estimated Study Start Date:	April 17, 2023
Estimated Study Completion Date:	July 7, 2025
NCT Number:	NCT05764122
URL	https://clinicaltrials.gov/ct2/show/NCT05764122

***Clinicaltrials.gov**

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. The Web site is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).

End